Skip to main content
    G

    Goodrx Holdings Inc (GDRX)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $3.51
    -0.05 (-1.40%)

    Market Cap: $1.21B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Goodrx Holdings Inc (GDRX) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Goodrx Holdings (GDRX) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Goodrx Holdings reported EPS of $0.04, in line with the $0.04 estimate. It beat the EPS estimate in 0 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    36%(9/25)
    Avg Surprise
    +8.49%

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.08
    Range$0.07 - $0.11
    15 analysts
    Revenue Consensus
    $206.12M
    Range$192.86M - $215.36M
    14 analysts

    Next Report

    GDRX has an expected report date of Feb 23, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 11.1% below the $0.09 reported for the quarter ended Dec 31, 2025.

    GDRX Earnings Call

    The latest GDRX earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 25 quarters below that had an estimate, GDRX beat 9, missed 8 and matched 8. The widest gap in the table came in the quarter ended Sep 30, 2022, when EPS landed 75.00% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.04$0.04N/A0.00%In line-50.0%113 up, 4 downNov 9, 2026N/A
    Jun 30, 2026$0.04$0.04N/A0.00%In line-55.6%121 up, 2 downAug 5, 2026$200.41M
    Mar 31, 2026$0.07$0.07$0.05 - $0.090.00%In line-22.2%120 up, 6 downMay 6, 2026$194.01M
    Dec 31, 2025$0.09$0.09$0.08 - $0.11-1.85%Miss0.0%120 up, 6 downFeb 25, 2026$194.78M
    Sep 30, 2025$0.08$0.09$0.08 - $0.11-11.11%Miss0.0%121 up, 6 downNov 4, 2025$196.03M
    Jun 30, 2025$0.09$0.10$0.09 - $0.12-10.00%Miss+12.5%122 up, 3 downAug 6, 2025$203.07M
    Mar 31, 2025$0.09$0.10$0.08 - $0.11-5.96%Miss+12.5%122 up, 3 downMay 7, 2025$202.97M
    Dec 31, 2024$0.09$0.10$0.08 - $0.15-10.00%Miss+12.5%123 up, 4 downFeb 27, 2025$198.58M
    Sep 30, 2024$0.08$0.09$0.07 - $0.11-11.11%Miss+33.3%130 up, 0 downNov 7, 2024$195.25M
    Jun 30, 2024$0.08$0.09$0.08 - $0.11-11.11%Miss+14.3%140 up, 1 downAug 8, 2024$200.61M
    Mar 31, 2024$0.08$0.08$0.03 - $0.100.00%In line+14.3%150 up, 0 downMay 9, 2024$197.88M
    Dec 31, 2023$0.08$0.07$0.01 - $0.10+14.29%Beat+14.3%161 up, 0 downFeb 29, 2024$196.64M
    Sep 30, 2023$0.06$0.06$0.04 - $0.080.00%In line-14.3%140 up, 0 downNov 9, 2023$179.96M
    Jun 30, 2023$0.07$0.06$0.05 - $0.07+16.67%Beat+16.7%150 up, 0 downAug 9, 2023$189.68M
    Mar 31, 2023$0.07$0.06$0.05 - $0.07+16.67%Beat-30.0%161 up, 0 downMay 10, 2023$183.99M
    Dec 31, 2022$0.07$0.05$0.03 - $0.05+40.00%Beat-22.2%170 up, 0 downFeb 28, 2023$184.11M
    Sep 30, 2022$0.07$0.04$0.01 - $0.05+75.00%Beat-22.2%161 up, 0 downNov 8, 2022$187.32M
    Jun 30, 2022$0.06$0.04$0.01 - $0.05+50.00%Beat-25.0%140 up, 1 downAug 8, 2022$191.80M
    Mar 31, 2022$0.10$0.08$0.07 - $0.09+25.00%Beat+42.9%150 up, 0 downMay 9, 2022$203.33M
    Dec 31, 2021$0.09$0.10$0.09 - $0.11-10.00%Miss+12.5%130 up, 0 downFeb 28, 2022$213.26M
    Sep 30, 2021$0.09$0.09$0.07 - $0.100.00%In line0.0%13N/ANov 10, 2021$195.10M
    Jun 30, 2021$0.08$0.08$0.07 - $0.080.00%In line-99.8%13N/AAug 12, 2021$176.63M
    Mar 31, 2021$0.07$0.07$0.07 - $0.100.00%In lineN/A13N/AMay 13, 2021$160.43M
    Dec 31, 2020$0.08$0.06$0.06 - $0.07+33.33%BeatN/A14N/AMar 11, 2021$153.54M
    Sep 30, 2020$0.09$0.08$0.07 - $0.11+12.50%BeatN/A14N/ANov 12, 2020$140.45M
    Jun 30, 2020$42.71$0.10N/AN/AN/AN/AN/AN/AJul 2, 2020$123.30M
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.35, within 4 cents of the year before. It was $42.88 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.35N/A
    Dec 31, 2024$0.33+17.9%
    Dec 31, 2023$0.28N/A
    Dec 31, 2022$0.30N/A
    Dec 31, 2021$0.33-99.2%
    Dec 31, 2020$42.88N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 7,300 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20267,27714
    2026Q1Mar 31, 20266,73614
    2025Q4Dec 31, 20258,77616
    2025Q3Sep 30, 20258,31414
    2025Q2Jun 30, 20255,3949
    2025Q1Mar 31, 20259,57514
    2024Q4Dec 31, 20248,14116
    2024Q3Sep 30, 20248,32617

    2026Q2 Earnings Call

    Opening remarks

    Aubrey Reynolds Director of Investor Relations Thank you, operator. Good morning, everyone, and welcome to GoodRx's earnings conference call for the second quarter 2026. Joining me today are Wendy Barnes, our Chief Executive Officer; and Justin Fengler, our newly appointed Chief Financial Officer. Before we begin, I'd like to remind everyone that this call will contain forward-looking statements. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding management's plans, strategies, goals and objectives, our market opportunity, our anticipated financial performance, underlying trends in our business and industry, including ongoing changes in the pharmacy ecosystem, our value proposition, our long-term growth prospects, our direct and hybrid contracting approach, collaborations and partnerships with third parties, including our point-of-sale cash programs and our integrated savings program, our e-commerce strategy and our capital allocation priorities. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors. These factors, including the factors discussed in the Risk Factors section of our annual report on the Form 10-K for the year ended December 31, 2025, and our other filings with the Securities and Exchange Commission could cause actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements made on this call. Any such forward-looking statements represent management's estimates as of the date of this call, and we disclaim any obligation to update these statements even if subsequent events cause our views to change. In addition, we will be referencing certain non-GAAP metrics in today's remarks. We have reconciled each non-GAAP metric to the nearest GAAP metric in the company's earnings press release, which can be found on the overview page of our Investor Relations website at investors.goodrx.com. I'd also like to remind everyone that a replay of this call will become available there shortly as well. With that, I'll turn it over to Wendy.

    Wendy Barnes Chief Executive Officer Thank you, Aubrey, and thank you to everyone for joining us today. The second quarter was a strong quarter for GoodRx. We exceeded our revenue expectations, maintained disciplined profitability and saw meaningful consumer engagement across the platform. That performance was driven by the two strategic priorities we outlined at the beginning of the year. First, Pharma Direct, which is scaling quickly due to growing manufacturer adoption of consumer direct pricing programs and sustained strength in GLP-1 access. Second, subscriptions, which are becoming a central part of how we serve and retain consumers as illustrated by the launch of our newest offering, GoodRx Companion in May.

    Frequently Asked Questions About GDRX

    When is Goodrx Holdings's next earnings date?

    Goodrx Holdings's next earnings report is expected for Feb 23, 2027.

    Did GDRX beat earnings estimates last quarter?

    Goodrx Holdings reported EPS of $0.04 for the quarter ended Sep 30, 2026, in line with the $0.04 estimate.

    What EPS do analysts expect from GDRX next quarter?

    The consensus EPS estimate for Goodrx Holdings for the quarter ending Dec 31, 2026 is $0.08 from 15 analysts, with estimates from $0.07 to $0.11.

    How often does GDRX beat earnings estimates?

    Goodrx Holdings beat the EPS estimate in 0 of the last 8 quarters, with an average surprise of -4.87%.